Table: q1_q4_2021_prescription_drug_wac_increases , manufacturer_name like A*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

oshpd_id	manufacturer_name	date_reported	ndc_number	drug_product_description	wac_effective_date	wac_increase_amount	wac_after_increase	patent_expiration_date	drug_source_type	unit_sales_volume_in_us	unit_sales_volume_non_public_indicator	cost_increase_factors	cost_increase_factors_non_public_indicator	change_improvement_description	change_improvement_non_public_indicator	acquisition_date	company_acquired_from	acquisition_price	acquisition_price_non_public_indicator	acquisition_price_comment	wac_at_acquisition	wac_year_prior_to_acquisition	year_drug_introduced_to_market	wac_at_intro_to_market	supporting_documents	general_comments
Rx0000077	AbbVie	03/31/2021	00074081702	(adalimumab) HUMIRA 10MG/0.1ML PFS 2-PACK	01/01/2021	411.21	5968.18	11/14/2034	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2021	00074006702	(adalimumab) HUMIRA 1X80MG,0.8ML, 1X40MG,0.4ML PFS2PK	01/01/2021	616.83	8952.31	11/14/2034	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2021	00074061602	(adalimumab) HUMIRA 20MG/0.2ML PFS 2-PACK	01/01/2021	411.21	5968.18	11/14/2034	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2021	00074937402	(adalimumab) HUMIRA 20MG/0.4ML (2 SYRINGES)	01/01/2021	411.21	5968.18	11/14/2034	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2021	00074433902	(adalimumab) HUMIRA 40MG/0.8 ML (2 PENS)	01/01/2021	411.21	5968.18	11/14/2034	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2021	00074379902	(adalimumab) HUMIRA 40MG/0.8ML (2 SYRINGES)	01/01/2021	411.21	5968.18	11/14/2034	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2021	00074254003	(adalimumab) HUMIRA 80MG, 0.8ML PFS 3-PACK	01/01/2021	1233.65	17904.62	11/14/2034	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2021	00074012403	(adalimumab) HUMIRA 80MG,0.8mL 3 Pens	01/01/2021	1233.65	17904.62	11/14/2034	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2021	00074153903	(adalimumab) HUMIRA KIT 80MG/0.8ML, 40MG/0.4ML 3 PENS	01/01/2021	822.44	11936.40	11/14/2034	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2021	00074055402	(adalimumab) HUMIRA PEN, 40MG/0.4ML, 2 PENS	01/01/2021	411.21	5968.18	11/14/2034	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2021	00074024302	(adalimumab) HUMIRA PFS, 40MG/0.4ML, 2 SYRINGES	01/01/2021	411.21	5968.18	11/14/2034	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2021	00074433906	(adalimumab) HUMIRA, CROHN'S, 40MG/0.8 ML (6 PENS)	01/01/2021	1233.65	17904.62	11/14/2034	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2021	00074433907	(adalimumab) HUMIRA, PSORIASIS, 40MG/0.8ML (4 PENS)	01/01/2021	822.44	11936.40	11/14/2034	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2021	00074634702	(adalimumab) Humira, Single Dose Syringe, 10 mg/0.2mL	01/01/2021	411.21	5968.18	11/14/2034	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2021	00074347303	(leuprolide acetate) LUPRON 45MG 6MTH	01/01/2021	619.12	10604.85	02/05/2031	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2021	00074244003	(leuprolide acetate) Lupron Depot Ped, 15 mg PDS Kit	01/01/2021	208.29	3567.80	None	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2021	00074377903	(leuprolide acetate) LUPRON DEPOT PED, 3month, 11.25mg	01/01/2021	567.34	9718.03	None	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2021	00074969403	(leuprolide acetate) LUPRON DEPOT PED, 3month, 30mg	01/01/2021	624.87	10703.43	None	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2021	00074210803	(leuprolide acetate) Lupron Depot Ped, 7.5 mg PDS Kit	01/01/2021	104.17	1784.28	None	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2021	00074366303	(leuprolide acetate) Lupron Depot, 3 Month 11.25 mg PDS Kit	01/01/2021	259.77	4449.61	None	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2021	00074334603	(leuprolide acetate) Lupron Depot, 3 Month 22.5 mg PDS Kit	01/01/2021	309.55	5302.34	None	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2021	00074364103	(leuprolide acetate) Lupron Depot, 3.75 mg PDS Kit	01/01/2021	86.59	1483.19	None	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2021	00074368303	(leuprolide acetate) Lupron Depot, 4 Month 30 mg PDS Kit	01/01/2021	412.74	7069.80	None	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2021	00074364203	(leuprolide acetate) Lupron Depot, 7.5 mg PDS Kit	01/01/2021	103.18	1767.45	None	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2021	00074228203	(leuprolide acetate) Lupron Depot-Ped 11.25 mg PDS Kit	01/01/2021	189.11	3239.33	None	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2021	00074105305	(leuprolide acetate/norethindrone acetate) Lupaneta 11.25 mg (3 Month) Kit	01/01/2021	259.77	4449.61	None	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2021	00074105205	(leuprolide acetate/norethindrone acetate) Lupaneta, 3.75 mg (1 Month) Kit	01/01/2021	86.59	1483.19	None	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2021	00032121201	(lipase/protease/amylase) CREON 12000USP DELAYED-RELEASE 100CAP	01/01/2021	20.71	354.73	02/07/2030	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2021	00032121207	(lipase/protease/amylase) CREON 12000USP DELAYED-RELEASE 250CAP	01/01/2021	51.78	886.81	02/07/2030	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2021	00032122401	(lipase/protease/amylase) CREON 24000USP DELAYED-RELEASE 100CAP	01/01/2021	41.05	703.13	02/07/2030	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2021	00032122407	(lipase/protease/amylase) CREON 24000USP DELAYED-RELEASE 250CAP	01/01/2021	100.96	1729.52	02/07/2030	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2021	00032120370	(lipase/protease/amylase) CREON 3000USP DELAYED-RELEASE 70CAP	01/01/2021	6.13	104.93	02/07/2030	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2021	00032301613	(lipase/protease/amylase) CREON 36000USP DELAYED-RELEASE 100CAP	01/01/2021	62.33	1067.62	02/07/2030	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2021	00032301628	(lipase/protease/amylase) CREON 36000USP DELAYED-RELEASE 250CAP	01/01/2021	155.80	2668.74	02/07/2030	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2021	00032120601	(lipase/protease/amylase) CREON 6000USP DELAYED-RELEASE 100CAP	01/01/2021	10.37	177.47	02/07/2030	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000077	AbbVie	03/31/2021	00032120607	(lipase/protease/amylase) CREON 6000USP DELAYED-RELEASE 250CAP	01/01/2021	25.91	443.71	02/07/2030	Single Source Drug	None	1	AbbVie's pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000018	ACADIA Pharmaceuticals Inc.	09/30/2021	63090010030	NUPLAZID, 10mg, Oral Tablet, 30 tablets	07/10/2021	342.00	3980.00	03/23/2037	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions:. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which ACADIA believes is otherwise in the public domain or publicly available. (2) For the latest the latest patent expiration, please refer to Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”). (3) This drug was developed by ACADIA , therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000018	ACADIA Pharmaceuticals Inc.	09/30/2021	63090034030	NUPLAZID, 34 mg, Oral Capsule, 30 capsules	07/10/2021	342.00	3980.00	08/27/2038	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions:. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which ACADIA believes is otherwise in the public domain or publicly available. (2) For the latest the latest patent expiration, please refer to Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”). (3) This drug was developed by ACADIA , therefore the following fields related to drug acquisition have been left blank: ACQUISITION_DATE, ACQUIRED_FROM_COMPANY, ACQUISITION_PRICE, ACQUISITION_PRICE_NONPUBLIC, ACQUISITION_PRICE_COMMENT, WAC_AT_ACQUISITION, YEAR_INTRODUCED, WAC_AT_INTRODUCTION.
Rx0000278	Acella Pharamceuticals, LLC	09/30/2021	42192060840	Gabapentin 300mg/ 6ml Unit dose Lq 40ct	07/01/2021	40.00	125.00	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Columns 14 - 22 were left blank because this product was not acquired from another manufacturer in the last five years.
Rx0000021	Acorda Therapeutics, Inc.	03/31/2021	10144042760	AMPYRA (dalfampridine) Extended Release Tablets 10mg 60 Tablet Bottles	01/01/2021	278.75	3212.89	None	Innovator Multiple Source Drug	None	1	AMPYRA® is the company’s primary source of revenue while working to make this product and its Parkinson’s product available to patients	None	AMPYRA® has not been reformulated, but is the company’s primary source of revenue while working to make this product and its Parkinson’s product available to patients	None	None	None	None	None	None	None	None	None	None	None	There are no patents listed in the Orange book for Ampyra. Ampyra became subject to competition from generic versions of Ampyra starting in late 2018 as a result of an adverse U.S. federal district court ruling that invalidated certain Ampyra Orange book-listed patents.
Rx0000251	Actelion Pharmaceuticals US, Inc	03/31/2021	66215050115	OPSUMIT® (macitentan) Strength: 10 mg Package Size:15 Form: Tablet	01/15/2021	242.10	5285.85	04/18/2029	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2021.
Rx0000251	Actelion Pharmaceuticals US, Inc	03/31/2021	66215050130	OPSUMIT® (macitentan) Strength: 10 mg Package Size:30 Form: Tablet	01/15/2021	484.21	10571.70	04/18/2029	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2021.
Rx0000251	Actelion Pharmaceuticals US, Inc	03/31/2021	66215061006	UPTRAVI® (selexipag) Strength:1000 mcg Package Size:60 Form:Tablet	01/15/2021	881.08	19236.90	12/01/2036	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2021.
Rx0000251	Actelion Pharmaceuticals US, Inc	03/31/2021	66215061206	UPTRAVI® (selexipag) Strength:1200 mcg Package Size:60 Form:Tablet	01/15/2021	881.08	19236.90	12/01/2036	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2021.
Rx0000251	Actelion Pharmaceuticals US, Inc	03/31/2021	66215061406	UPTRAVI® (selexipag) Strength:1400 mcg Package Size:60 Form:Tablet	01/15/2021	881.08	19236.90	12/01/2036	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2021.
Rx0000251	Actelion Pharmaceuticals US, Inc	03/31/2021	66215061606	UPTRAVI® (selexipag) Strength:1600 mcg Package Size:60 Form:Tablet	01/15/2021	881.08	19236.90	12/01/2036	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2021.
Rx0000251	Actelion Pharmaceuticals US, Inc	03/31/2021	66215060214	UPTRAVI® (selexipag) Strength:200 mcg Package Size:140 Form:Tablet	01/15/2021	1321.95	28862.61	12/01/2036	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2021.
Rx0000251	Actelion Pharmaceuticals US, Inc	03/31/2021	66215060206	UPTRAVI® (selexipag) Strength:200 mcg Package Size:60 Form:Tablet	01/15/2021	566.55	12369.69	12/01/2036	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2021.
Rx0000251	Actelion Pharmaceuticals US, Inc	03/31/2021	66215062820	UPTRAVI® (selexipag) Strength:200+800 mcg Package Size:200 Form:Tablet	01/15/2021	1321.94	28862.38	12/01/2036	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2021.
Rx0000251	Actelion Pharmaceuticals US, Inc	03/31/2021	66215060406	UPTRAVI® (selexipag) Strength:400 mcg Package Size:60 Form:Tablet	01/15/2021	881.08	19236.90	12/01/2036	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2021.
Rx0000251	Actelion Pharmaceuticals US, Inc	03/31/2021	66215060606	UPTRAVI® (selexipag) Strength:600 mcg Package Size:60 Form:Tablet	01/15/2021	881.08	19236.90	12/01/2036	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2021.
Rx0000251	Actelion Pharmaceuticals US, Inc	03/31/2021	66215060806	UPTRAVI® (selexipag) Strength:800 mcg Package Size:60 Form:Tablet	01/15/2021	881.08	19236.90	12/01/2036	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2021.
Rx0000203	Aegerion Pharmaceuticals, Inc.	03/31/2021	76431011001	JUXTAPID 10 MG CAPS, bottle of 28 capsules	02/01/2021	1788.59	46502.12	08/19/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000203	Aegerion Pharmaceuticals, Inc.	03/31/2021	76431012001	JUXTAPID 20 MG CAPS, bottle of 28 capsules	02/01/2021	1788.59	46502.12	08/19/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000203	Aegerion Pharmaceuticals, Inc.	03/31/2021	76431013001	JUXTAPID 30 MG CAPS, bottle of 28 capsules	02/01/2021	1788.59	46502.12	08/19/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000203	Aegerion Pharmaceuticals, Inc.	03/31/2021	76431010501	JUXTAPID 5 MG CAPS - bottle of 28	02/01/2021	1788.59	46502.12	08/19/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000203	Aegerion Pharmaceuticals, Inc.	03/31/2021	76431021001	MYALEPT 11.3MG VIAL	02/01/2021	203.73	5297.05	12/31/2027	Single Source Drug	None	1	None	1	None	1	01/12/2015	Astra Zeneca	325000000	None	None	3493.00	None	2014	3493.00	None	None
Rx0000085	Akorn Inc	12/31/2021	17478030703	Azasite 1% Opth Soln 10mg, 2.5mL, 1 Bottle	12/30/2021	16.50	222.71	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000085	Akorn Inc	12/31/2021	76478000105	Betimol 0.25% Opth Solution 2.56mg/mL, 5mL, 1 Bottle	12/30/2021	10.22	137.98	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000085	Akorn Inc	12/31/2021	76478000215	Betimol 0.5% Opth Solution 5.12mg/mL, 15mL, 1 Bottle	12/30/2021	32.63	440.52	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000085	Akorn Inc	12/31/2021	76478000205	Betimol 0.5% Opth Solution 5.12mg/mL, 5mL, 1 Bottle	12/30/2021	11.29	152.36	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000085	Akorn Inc	12/31/2021	76478000210	Betimol 0.50% Opth Solution 5.12mg/mL, 10mL, 1 Bottle	12/30/2021	21.68	292.69	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000085	Akorn Inc	12/31/2021	17478060930	Zioptan Ophth Sol .0015% .3mL/.0045mg, .3mL-30 UD pk	12/30/2021	17.04	230.05	05/28/2029	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000020	Allergan	03/31/2021	00023320503	(bimatoprost) LUMIGAN 0.01% EYE DROPS 2.5 mL	01/01/2021	10.34	217.16	06/13/2027	Single Source Drug	None	1	AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000020	Allergan	03/31/2021	00023320505	(bimatoprost) LUMIGAN 0.01% EYE DROPS 5 mL	01/01/2021	20.67	434.14	06/13/2027	Single Source Drug	None	1	AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000020	Allergan	03/31/2021	00023320508	(bimatoprost) LUMIGAN 0.01% EYE DROPS 7.5 mL	01/01/2021	31.01	651.18	06/13/2027	Single Source Drug	None	1	AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000020	Allergan	03/31/2021	00023932110	(brimonidine tartrate) ALPHAGAN P 0.1% DROPS 10 mL	01/01/2021	16.79	352.56	03/02/2024	Single Source Drug	None	1	AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000020	Allergan	03/31/2021	00023932115	(brimonidine tartrate) ALPHAGAN P 0.1% DROPS 15 mL	01/01/2021	25.19	528.92	03/02/2024	Single Source Drug	None	1	AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000020	Allergan	03/31/2021	00023932105	(brimonidine tartrate) ALPHAGAN P 0.1% DROPS 5 mL	01/01/2021	8.40	176.36	03/02/2024	Single Source Drug	None	1	AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000020	Allergan	03/31/2021	00023917710	(brimonidine tartrate) ALPHAGAN P 0.15% EYE DROPS 10 mL	01/01/2021	17.90	375.94	01/28/2022	Innovator Multiple Source Drug	None	1	AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000020	Allergan	03/31/2021	00023917715	(brimonidine tartrate) ALPHAGAN P 0.15% EYE DROPS 15 mL	01/01/2021	26.86	563.97	01/28/2022	Innovator Multiple Source Drug	None	1	AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000020	Allergan	03/31/2021	00023917705	(brimonidine tartrate) ALPHAGAN P 0.15% EYE DROPS 5 mL	01/01/2021	8.95	188.02	01/28/2022	Innovator Multiple Source Drug	None	1	AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000020	Allergan	03/31/2021	00023921110	(brimonidine tartrate/timolol maleate) COMBIGAN 0.2%-0.5% EYE DROPS 10 mL	01/01/2021	18.52	388.83	04/19/2022	Single Source Drug	None	1	AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000020	Allergan	03/31/2021	00023921115	(brimonidine tartrate/timolol maleate) COMBIGAN 0.2%-0.5% EYE DROPS 15 mL	01/01/2021	27.77	583.20	04/19/2022	Single Source Drug	None	1	AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000020	Allergan	03/31/2021	00023921105	(brimonidine tartrate/timolol maleate) COMBIGAN 0.2%-0.5% EYE DROPS 5 mL	01/01/2021	9.26	194.41	04/19/2022	Single Source Drug	None	1	AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000020	Allergan	03/31/2021	00456040010	(ceftaroline fosamil acetate) TEFLARO 400 MG VIAL 10	01/01/2021	100.86	2118.13	02/10/2031	Single Source Drug	None	1	AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000020	Allergan	03/31/2021	00456040001	(ceftaroline fosamil acetate) TEFLARO 400 MG VIAL 1-Inner Pack	01/01/2021	10.09	211.81	02/10/2031	Single Source Drug	None	1	AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000020	Allergan	03/31/2021	00456060010	(ceftaroline fosamil acetate) TEFLARO 600 MG VIAL 10	01/01/2021	100.86	2118.13	02/10/2031	Single Source Drug	None	1	AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000020	Allergan	03/31/2021	00456060001	(ceftaroline fosamil acetate) TEFLARO 600 MG VIAL 1-Inner Pack	01/01/2021	10.09	211.81	02/10/2031	Single Source Drug	None	1	AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000020	Allergan	03/31/2021	00023916330	(cyclosporine) RESTASIS 0.05% EYE EMULSION 30	01/01/2021	14.64	307.43	None	Single Source Drug	None	1	AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000020	Allergan	03/31/2021	00023916360	(cyclosporine) RESTASIS 0.05% EYE EMULSION 60	01/01/2021	29.28	614.89	None	Single Source Drug	None	1	AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000020	Allergan	03/31/2021	00023530105	(cyclosporine) RESTASIS MULTIDOSE 0.05% EYE 5.5 mL	01/01/2021	29.28	614.89	05/11/2034	Single Source Drug	None	1	AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000020	Allergan	03/31/2021	61874010060	(eluxadoline) VIBERZI 100 MG TABLET 60	01/01/2021	65.87	1383.26	03/14/2033	Single Source Drug	None	1	AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000020	Allergan	03/31/2021	61874007560	(eluxadoline) VIBERZI 75 MG TABLET 60	01/01/2021	65.87	1383.26	03/14/2033	Single Source Drug	None	1	AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000020	Allergan	03/31/2021	00456201001	(escitalopram oxalate) LEXAPRO 10 MG TABLET 100	01/01/2021	60.24	1264.96	02/12/2023	Innovator Multiple Source Drug	None	1	AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000020	Allergan	03/31/2021	00456202001	(escitalopram oxalate) LEXAPRO 20 MG TABLET 100	01/01/2021	62.86	1319.99	02/12/2023	Innovator Multiple Source Drug	None	1	AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000020	Allergan	03/31/2021	00456200501	(escitalopram oxalate) LEXAPRO 5 MG TABLET 100	01/01/2021	57.61	1209.86	02/12/2023	Innovator Multiple Source Drug	None	1	AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000020	Allergan	03/31/2021	00456220228	(levomilnacipran HCl) FETZIMA 20-40 MG TITRATION PAK 1 EA	01/01/2021	19.25	404.20	05/23/2032	Single Source Drug	None	1	AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000020	Allergan	03/31/2021	00456221230	(levomilnacipran HCl) FETZIMA ER 120 MG CAPSULE 30	01/01/2021	20.62	433.06	05/23/2032	Single Source Drug	None	1	AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000020	Allergan	03/31/2021	00456222030	(levomilnacipran HCl) FETZIMA ER 20 MG CAPSULE 30	01/01/2021	20.62	433.06	05/23/2032	Single Source Drug	None	1	AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000020	Allergan	03/31/2021	00456224030	(levomilnacipran HCl) FETZIMA ER 40 MG CAPSULE 30	01/01/2021	20.62	433.06	05/23/2032	Single Source Drug	None	1	AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000020	Allergan	03/31/2021	00456228030	(levomilnacipran HCl) FETZIMA ER 80 MG CAPSULE 30	01/01/2021	20.62	433.06	05/23/2032	Single Source Drug	None	1	AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000020	Allergan	03/31/2021	00023585801	(levonorgestrel) LILETTA 52 MG SYSTEM 1	01/01/2021	58.23	845.10	03/22/2034	Single Source Drug	None	1	AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000020	Allergan	03/31/2021	00456120130	(linaclotide) LINZESS 145 MCG CAPSULE 30	01/01/2021	22.25	467.27	08/16/2033	Single Source Drug	None	1	AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000020	Allergan	03/31/2021	00456120230	(linaclotide) LINZESS 290 MCG CAPSULE 30	01/01/2021	22.25	467.27	08/16/2033	Single Source Drug	None	1	AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000020	Allergan	03/31/2021	00456120330	(linaclotide) LINZESS 72 MCG CAPSULE 30	01/01/2021	22.25	467.27	08/16/2033	Single Source Drug	None	1	AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000020	Allergan	03/31/2021	00456121430	(memantine HCl/donepezil HCl) NAMZARIC 14 MG-10 MG CAPSULE 30	01/01/2021	24.29	510.08	12/05/2029	Single Source Drug	None	1	AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000020	Allergan	03/31/2021	00456122130	(memantine HCl/donepezil HCl) NAMZARIC 21 MG-10 MG CAPSULE 30	01/01/2021	24.29	510.08	12/05/2029	Single Source Drug	None	1	AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000020	Allergan	03/31/2021	00456122830	(memantine HCl/donepezil HCl) NAMZARIC 28 MG-10 MG CAPSULE 30	01/01/2021	24.29	510.08	12/05/2029	Single Source Drug	None	1	AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000020	Allergan	03/31/2021	00456120730	(memantine HCl/donepezil HCl) NAMZARIC 7 MG-10 MG CAPSULE 30	01/01/2021	24.29	510.08	12/05/2029	Single Source Drug	None	1	AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000020	Allergan	03/31/2021	00456122929	(memantine HCl/donepezil HCl) NAMZARIC TITRATION PACK 1 EA	01/01/2021	22.67	476.07	12/05/2029	Single Source Drug	None	1	AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000020	Allergan	03/31/2021	00456151060	(milnacipran HCl) SAVELLA 100 MG TABLET 60	01/01/2021	20.05	421.08	09/19/2029	Single Source Drug	None	1	AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000020	Allergan	03/31/2021	00456151260	(milnacipran HCl) SAVELLA 12.5 MG TABLET 60	01/01/2021	20.05	421.08	09/19/2029	Single Source Drug	None	1	AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000020	Allergan	03/31/2021	00456152560	(milnacipran HCl) SAVELLA 25 MG TABLET 60	01/01/2021	20.05	421.08	09/19/2029	Single Source Drug	None	1	AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000020	Allergan	03/31/2021	00456155060	(milnacipran HCl) SAVELLA 50 MG TABLET 60	01/01/2021	20.05	421.08	09/19/2029	Single Source Drug	None	1	AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000020	Allergan	03/31/2021	00456150055	(milnacipran HCl) SAVELLA TITRATION PACK 1 EA	01/01/2021	18.38	385.99	09/19/2029	Single Source Drug	None	1	AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000020	Allergan	03/31/2021	00456141030	(nebivolol HCl) BYSTOLIC 10 MG TABLET 30	01/01/2021	7.52	157.92	12/17/2021	Single Source Drug	None	1	AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000020	Allergan	03/31/2021	00456141090	(nebivolol HCl) BYSTOLIC 10 MG TABLET 90	01/01/2021	22.56	473.76	12/17/2021	Single Source Drug	None	1	AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000020	Allergan	03/31/2021	00456140263	(nebivolol HCl) BYSTOLIC 2.5 MG TABLET 10 X 10 UD	01/01/2021	25.54	536.40	12/17/2021	Single Source Drug	None	1	AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000020	Allergan	03/31/2021	00456140230	(nebivolol HCl) BYSTOLIC 2.5 MG TABLET 30	01/01/2021	7.52	157.92	12/17/2021	Single Source Drug	None	1	AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000020	Allergan	03/31/2021	00456142030	(nebivolol HCl) BYSTOLIC 20 MG TABLET 30	01/01/2021	7.52	157.92	12/17/2021	Single Source Drug	None	1	AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000020	Allergan	03/31/2021	00456142090	(nebivolol HCl) BYSTOLIC 20 MG TABLET 90	01/01/2021	22.56	473.76	12/17/2021	Single Source Drug	None	1	AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000020	Allergan	03/31/2021	00456140563	(nebivolol HCl) BYSTOLIC 5 MG TABLET 10 X 10 UD	01/01/2021	25.54	536.40	12/17/2021	Single Source Drug	None	1	AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000020	Allergan	03/31/2021	00456140530	(nebivolol HCl) BYSTOLIC 5 MG TABLET 30	01/01/2021	7.52	157.92	12/17/2021	Single Source Drug	None	1	AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000020	Allergan	03/31/2021	00456140590	(nebivolol HCl) BYSTOLIC 5 MG TABLET 90	01/01/2021	22.56	473.76	12/17/2021	Single Source Drug	None	1	AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000020	Allergan	03/31/2021	00430042014	(norethindrone acetate-ethinyl estradiol/ferrous fumarate) LO LOESTRIN FE 1-10 TABLET 5 x 28	01/01/2021	36.94	775.71	02/02/2029	Single Source Drug	None	1	AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000020	Allergan	03/31/2021	00023586230	(norethindrone acetate-ethinyl estradiol/ferrous fumarate) TAYTULLA 1 MG-20 MCG CAPSULE 5x28	01/01/2021	49.07	1030.55	None	Innovator Multiple Source Drug	None	1	AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000020	Allergan	03/31/2021	58914017110	(sucralfate) CARAFATE 1 GM TABLET 100	01/01/2021	20.40	428.34	None	Innovator Multiple Source Drug	None	1	AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000020	Allergan	03/31/2021	58914017014	(sucralfate) CARAFATE 1 GM/10 ML SUSP 14 fl. oz.	01/01/2021	10.99	230.73	None	Innovator Multiple Source Drug	None	1	AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000020	Allergan	03/31/2021	00456046101	(thyroid,pork) ARMOUR THYROID 120 MG TABLET 100	01/01/2021	8.07	169.37	None	Innovator Multiple Source Drug	None	1	AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000020	Allergan	03/31/2021	00456045701	(thyroid,pork) ARMOUR THYROID 15 MG TABLET 100	01/01/2021	3.37	70.82	None	Innovator Multiple Source Drug	None	1	AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000020	Allergan	03/31/2021	00456046201	(thyroid,pork) ARMOUR THYROID 180 MG TABLET 100	01/01/2021	6.04	126.77	None	Single Source Drug	None	1	AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000020	Allergan	03/31/2021	00456046301	(thyroid,pork) ARMOUR THYROID 240 MG TABLET 100	01/01/2021	7.33	153.92	None	Single Source Drug	None	1	AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000020	Allergan	03/31/2021	00456045801	(thyroid,pork) ARMOUR THYROID 30 MG TABLET 100	01/01/2021	3.96	83.15	None	Innovator Multiple Source Drug	None	1	AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000020	Allergan	03/31/2021	00456046401	(thyroid,pork) ARMOUR THYROID 300 MG TABLET 100	01/01/2021	8.62	181.08	None	Single Source Drug	None	1	AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000020	Allergan	03/31/2021	00456045901	(thyroid,pork) ARMOUR THYROID 60 MG TABLET 100	01/01/2021	4.40	92.38	None	Innovator Multiple Source Drug	None	1	AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000020	Allergan	03/31/2021	00456046001	(thyroid,pork) ARMOUR THYROID 90 MG TABLET 100	01/01/2021	6.89	144.72	None	Innovator Multiple Source Drug	None	1	AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000020	Allergan	03/31/2021	00456111030	(vilazodone HCl) VIIBRYD 10 MG TABLET 30	01/01/2021	14.29	300.14	12/05/2022	Single Source Drug	None	1	AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000020	Allergan	03/31/2021	00456110130	(vilazodone HCl) VIIBRYD 10-20 MG STARTER PACK 1 EA	01/01/2021	14.29	300.14	12/05/2022	Single Source Drug	None	1	AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000020	Allergan	03/31/2021	00456112030	(vilazodone HCl) VIIBRYD 20 MG TABLET 30	01/01/2021	14.29	300.14	12/05/2022	Single Source Drug	None	1	AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000020	Allergan	03/31/2021	00456114030	(vilazodone HCl) VIIBRYD 40 MG TABLET 30	01/01/2021	14.29	300.14	12/05/2022	Single Source Drug	None	1	AbbVie's (Allergan) pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by AbbVie to ensure patient access to life-saving and life-changing medications; e) overall research and development costs.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000201	Almirall LLC	03/31/2021	16110050201	Acticlate Oral Tablet 150 MG 60 tablet	01/02/2021	66.14	2270.97	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000201	Almirall LLC	03/31/2021	16110050101	Acticlate Oral Tablet 75 MG 60 tablet	01/02/2021	66.14	2270.97	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000201	Almirall LLC	03/31/2021	16110036760	Aczone 5% Gel 60g US	01/02/2021	20.62	708.05	None	Single Source Drug	None	1	None	1	None	1	09/21/2018	Allergan	None	1	None	593.63	542.13	2014	397.62	None	None
Rx0000201	Almirall LLC	03/31/2021	16110036790	Aczone 5% Gel 90g US	01/02/2021	27.05	928.73	None	Single Source Drug	None	1	None	1	None	1	09/21/2018	Allergan	None	1	None	778.65	771.10	2014	569.12	None	None
Rx0000201	Almirall LLC	03/31/2021	16110052660	Aczone 7,5% Gel 60g US	01/02/2021	20.62	708.04	11/18/2033	Single Source Drug	None	1	None	1	None	1	09/21/2018	Allergan	None	1	None	593.63	542.13	2014	397.62	None	None
Rx0000201	Almirall LLC	03/31/2021	16110052690	Aczone 7,5% Gel 90g US	01/02/2021	27.05	928.73	11/18/2033	Single Source Drug	None	1	None	1	None	1	09/21/2018	Allergan	None	1	None	778.65	771.10	2014	569.12	None	None
Rx0000201	Almirall LLC	03/31/2021	16110051815	Altabax 1% Ointment 15 g US	01/02/2021	9.45	324.48	02/14/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000201	Almirall LLC	03/31/2021	16110051830	Altabax 1% Ointment 30 g US	01/02/2021	18.14	622.81	02/14/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000201	Almirall LLC	03/31/2021	16110003412	Cordran Cream 0,025% 120 g US	01/02/2021	14.62	501.82	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000201	Almirall LLC	03/31/2021	16110003512	Cordran Cream 0,05% 120 g US	01/02/2021	36.72	1260.73	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000201	Almirall LLC	03/31/2021	16110005212	Cordran Lotion 0,05% 120 ml US	01/02/2021	36.72	1260.73	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000201	Almirall LLC	03/31/2021	16110002660	Cordran Ointment 0,05% 60 g US	01/02/2021	22.16	760.97	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000201	Almirall LLC	03/31/2021	16110081230	Fluoroplex Cream 1% 30g US	01/02/2021	27.03	927.95	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000201	Almirall LLC	03/31/2021	16110007130	Veltin Gel 1.2%/0.025% tube 30 g US	01/02/2021	13.88	476.62	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000201	Almirall LLC	03/31/2021	16110007160	Veltin Gel 1.2%/0.025% tube 60 g US	01/02/2021	26.14	897.37	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000201	Almirall LLC	03/31/2021	16110011100	Verdeso Foam 0,05% 100g Aerosol	01/02/2021	29.77	1022.18	08/13/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000201	Almirall LLC	03/31/2021	16110008045	Xolegel Gel 2% 45 g US	01/02/2021	23.59	809.87	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000037	AMAG Pharmaceuticals, Inc.	09/30/2021	59338077501	ferumoxytol 510MG/17 mL Feraheme 510mg (1 vial package size, injectable solution)	07/01/2021	34.77	1193.62	06/30/2023	Single Source Drug	None	1	Pricing is a complex construct which requires a broad analysis of many factors across the organization. Changes in our WAC, or list price, for a product may not be solely dependent on or determined by the factors related to the product impacted by the price increase. As a part of our business model, we perform additional research to monitor safety, understand real life experiences, and develop better delivery mechanisms, dosage, and improved product formulations. We may also conduct additional clinical trials to expand product labels in the same therapeutic area or in new indications. We do not maintain records demonstrating how these and other costs are taken into consideration in making particular pricing decisions. Often the investment in such endeavors is spread over many years and cannot be captured in a single change in WAC. For example, as a result of these types of activities, we received FDA approval for an expanded label for Feraheme in early 2018 to allow treatment of all eligible adults with iron deficiency anemia. The distribution of patients across Commercial and Government insurers and the reimbursement landscape for prescribers are constantly changing and must be taken into consideration to the extent they are known or can be anticipated. Pricing decisions may include current trends and anticipated changes in the discounts, service fees, and rebates that are paid to insurers, group purchasing organizations, pharmacy benefit managers, government agencies, hospitals, physicians, wholesalers, pharmacies and other third parties to ensure that patients are able to have broad access and receive appropriate levels of care and support in connection with our products. In addition, we assess the competitive landscape which is a factor used by payers when making access decisions. We would also like to clarify that the WAC prices referenced in our report are not representative of the net costs to the state, insurers or the public.	None	This WAC increase is not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000037	AMAG Pharmaceuticals, Inc.	03/31/2021	59338077501	ferumoxytol 510MG/17 mL Feraheme 510mg Each	01/01/2021	44.57	1158.85	06/30/2023	Single Source Drug	None	1	Pricing is a complex construct which requires a broad analysis of many factors across the organization. Changes in our WAC, or list price, for a product may not be solely dependent on or determined by the factors related to the product impacted by the price increase. _x000D_ As a part of our business model at AMAG Pharmaceuticals, we perform additional research to monitor safety, understand real life experiences, and develop better delivery mechanisms, dosage, and improved product formulations. We may also conduct additional clinical trials to expand product labels in the same therapeutic area or in a new indications. Often the investment in such endeavors is spread over many years and cannot be captured in a single change in WAC. For example, as a result of these types of activities, we received FDA approval for an expanded label for Feraheme in early 2018 to allow treatment of all eligible adults with iron deficiency anemia. _x000D_ The distribution of patients across Commercial and Government insurers and the reimbursement landscape for prescribers are constantly changing and must be taken into consideration to the extent they are known or can be anticipated. Pricing decisions may include current trends and anticipated changes in the discounts, service fees, and rebates that are paid to insurers, group purchasing organizations, pharmacy benefit managers, government agencies, hospitals, physicians, wholesalers, pharmacies and other third parties to ensure that patients are able to have broad access and receive appropriate levels of care and support in connection with our products. _x000D_ Finally, a key consideration in determining a WAC change for Feraheme is based on the fact that Medicare Average Sales Price (ASP) is the primary reimbursement basis for most prescribers of Feraheme. Our strategy is to maintain a stable ASP for Feraheme, as this is critical to ensure continued broad access for patients. The reported ASP changes on a quarterly basis and is impacted by many of the factors identified above relating to the level of discounts and fees paid, as well as demand and forecasted inventory._x000D_ In addition, we assess the competitive landscape which is a factor used by payers when making access decisions. _x000D_ We would also like to clarify that the WAC prices referenced in our report are not representative of the net costs to the state, insurers or the public._x000D_	None	This WAC increase is not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	Feraheme was developed by AMAG and not subject to acquisition reporting
Rx0000037	AMAG Pharmaceuticals, Inc.	03/31/2021	59338077510	ferumoxytol 510MG/17 mL Feraheme 510mg/17 mL CTN/10	01/01/2021	445.70	11588.50	06/30/2023	Single Source Drug	None	1	Pricing is a complex construct which requires a broad analysis of many factors across the organization. Changes in our WAC, or list price, for a product may not be solely dependent on or determined by the factors related to the product impacted by the price increase. _x000D_ As a part of our business model at AMAG Pharmaceuticals, we perform additional research to monitor safety, understand real life experiences, and develop better delivery mechanisms, dosage, and improved product formulations. We may also conduct additional clinical trials to expand product labels in the same therapeutic area or in a new indications. Often the investment in such endeavors is spread over many years and cannot be captured in a single change in WAC. For example, as a result of these types of activities, we received FDA approval for an expanded label for Feraheme in early 2018 to allow treatment of all eligible adults with iron deficiency anemia. _x000D_ The distribution of patients across Commercial and Government insurers and the reimbursement landscape for prescribers are constantly changing and must be taken into consideration to the extent they are known or can be anticipated. Pricing decisions may include current trends and anticipated changes in the discounts, service fees, and rebates that are paid to insurers, group purchasing organizations, pharmacy benefit managers, government agencies, hospitals, physicians, wholesalers, pharmacies and other third parties to ensure that patients are able to have broad access and receive appropriate levels of care and support in connection with our products. _x000D_ Finally, a key consideration in determining a WAC change for Feraheme is based on the fact that Medicare Average Sales Price (ASP) is the primary reimbursement basis for most prescribers of Feraheme. Our strategy is to maintain a stable ASP for Feraheme, as this is critical to ensure continued broad access for patients. The reported ASP changes on a quarterly basis and is impacted by many of the factors identified above relating to the level of discounts and fees paid, as well as demand and forecasted inventory._x000D_ In addition, we assess the competitive landscape which is a factor used by payers when making access decisions. _x000D_ We would also like to clarify that the WAC prices referenced in our report are not representative of the net costs to the state, insurers or the public._x000D_	None	This WAC increase is not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	Feraheme was developed by AMAG and not subject to acquisition reporting
Rx0000050	Amarin Pharma, Inc.	12/31/2021	52937000120	Vascepa(Icosapent ethyl) 120 1g	12/29/2021	10.33	354.55	06/28/2033	Single Source Drug	4470446	None	Two recent independent third-party analyses of Vascepa have shown it to be highly cost effective based upon the results of the Vascepa outcomes study. • The Institute for Clinical and Economic Review (ICER), an independent drug price watchdog group, determined Vascepa cost-effective even against its most stringent standard (<$50,000 per QALY), a rare finding for this organization in its evaluation of branded drug prices. It found that if Vascepa were priced 2 times higher than its current price, it would still be cost-effective6. The price increase that Amarin instituted for Vascepa as of December 31, 2019 is substantially lower than this threshold. • On November 16, 2019, findings from a second independently developed cost-effectiveness analysis of Vascepa were disclosed in an abstract and corresponding presentation as part of the 2019 Scientific Sessions of the American Heart Association (AHA) in Philadelphia, PA. This cost-effectiveness analysis found that Vascepa was a dominant strategy (i.e., cost saving) in 70% of simulations, offering the rare finding of better outcomes at lower healthcare costs. In probabilistic sensitivity analysis, >85% of simulations indicated that Vascepa would be cost-effective (i.e., < $50,000 per QALY gained) compared with placebo. Therefore, Vascepa demonstrated exceptional benefit, with CV event reduction plus cost-savings in the majority of simulations.6 1. Bhatt DL, Steg PG, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med 2019;380:11-22. 2. American Diabetes Association. [web annotation]. Diabetes Care 2019;42(Suppl.1):S103–S123. https://hyp.is/JHhz_lCrEembFJ9LIVBZIw/care.diabetesjournals.org/content/42/Supplement_1/S103. Updated March 27, 2019. Accessed March 28, 2019. 3. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2019; ehz455. doi: 10.1093/eurheartj/ehz455. 4. Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2019; 40(39):3215-3217. doi: 10.1093/eurheartj/ehz687. 5. Orringer CE, Jacobson TA, Maki KC. National Lipid Association scientific statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high- or very-high ASCVD risk. J Clin Lipidol. 2019. doi: 10.1016/j.jacl.2019.10.014. 6. Institute for Clinical and Economic Review. Final Evidence Report. Additive Therapies for Cardiovascular Disease: Effectiveness and Value. https://icer-review.org/material/cvd-final-evidence-report/. Posted October 17, 2019. Accessed October 17, 2019. 7. Weintraub WS, Bhatt DL, Zhang A, et al. Cost-Effectiveness of icosapent ethyl in REDUCE-IT. Presented at American Heart Association Scientific Sessions 2019. November 16, 2019. Philadelphia, PA.	None	On December 13, 2019, Amarin announced a major milestone in preventative cardiology with a new FDA Approved indication for Vascepa® (icosapent ethyl). After more than a decade of development and testing, Vascepa in now the first and only drug approved by the FDA • as an adjunct to maximally tolerated statin therapy to reduce the risk of MI, stroke, coronary revascularization, and unstable angina requiring hospitalization in adult patients with elevated triglycerides =150 mg/dl and o Established cardiovascular disease, or o Diabetes and two or more additional risk factors for cardiovascular disease The FDA approval was based on the landmark REDUCE-IT® cardiovascular (CV) outcomes study, which showed, incremental to statin therapy, that Vascepa 4 g/day versus placebo provided a relative risk reduction of approximately 25% or more for the study’s primary and key secondary composite endpoints of major adverse cardiovascular events. Vascepa also showed robust relative risk reductions in each of the components of the primary composite endpoint, including myocardial infarction, stroke and cardiovascular death.1 The REDUCE-IT results have been characterized by leading physicians as the most significant advance in preventative cardiovascular care since the introduction of statin therapy. Based on the results of the Vascepa outcomes study, multiple professional societies have updated guidelines or issue advisories to incorporate Icosapent Ethyl, including the American Diabetes Association2, the European Society of Cardiology3,4, and the National Lipid Association.5 1. Bhatt DL, Steg PG, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med 2019;380:11-22. 2. American Diabetes Association. [web annotation]. Diabetes Care 2019;42(Suppl.1):S103–S123. https://hyp.is/JHhz_lCrEembFJ9LIVBZIw/care.diabetesjournals.org/content/42/Supplement_1/S103. Updated March 27, 2019. Accessed March 28, 2019. 3. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2019; ehz455. doi: 10.1093/eurheartj/ehz455. 4. Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2019; 40(39):3215-3217. doi: 10.1093/eurheartj/ehz687. 5. Orringer CE, Jacobson TA, Maki KC. National Lipid Association scientific statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high- or very-high ASCVD risk. J Clin Lipidol. 2019. doi: 10.1016/j.jacl.2019.10.014. 6. Institute for Clinical and Economic Review. Final Evidence Report. Additive Therapies for Cardiovascular Disease: Effectiveness and Value. https://icer-review.org/material/cvd-final-evidence-report/. Posted October 17, 2019. Accessed October 17, 2019. 7. Weintraub WS, Bhatt DL, Zhang A, et al. Cost-Effectiveness of icosapent ethyl in REDUCE-IT. Presented at American Heart Association Scientific Sessions 2019. November 16, 2019. Philadelphia, PA.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000050	Amarin Pharma, Inc.	12/31/2021	52937000340	Vascepa(Icosapent ethyl) 240 500mg	12/29/2021	12.08	414.81	06/28/2033	Single Source Drug	4475	None	Two recent independent third-party analyses of Vascepa have shown it to be highly cost effective based upon the results of the Vascepa outcomes study. • The Institute for Clinical and Economic Review (ICER), an independent drug price watchdog group, determined Vascepa cost-effective even against its most stringent standard (<$50,000 per QALY), a rare finding for this organization in its evaluation of branded drug prices. It found that if Vascepa were priced 2 times higher than its current price, it would still be cost-effective6. The price increase that Amarin instituted for Vascepa as of December 31, 2019 is substantially lower than this threshold. • On November 16, 2019, findings from a second independently developed cost-effectiveness analysis of Vascepa were disclosed in an abstract and corresponding presentation as part of the 2019 Scientific Sessions of the American Heart Association (AHA) in Philadelphia, PA. This cost-effectiveness analysis found that Vascepa was a dominant strategy (i.e., cost saving) in 70% of simulations, offering the rare finding of better outcomes at lower healthcare costs. In probabilistic sensitivity analysis, >85% of simulations indicated that Vascepa would be cost-effective (i.e., < $50,000 per QALY gained) compared with placebo. Therefore, Vascepa demonstrated exceptional benefit, with CV event reduction plus cost-savings in the majority of simulations.6 1. Bhatt DL, Steg PG, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med 2019;380:11-22. 2. American Diabetes Association. [web annotation]. Diabetes Care 2019;42(Suppl.1):S103–S123. https://hyp.is/JHhz_lCrEembFJ9LIVBZIw/care.diabetesjournals.org/content/42/Supplement_1/S103. Updated March 27, 2019. Accessed March 28, 2019. 3. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2019; ehz455. doi: 10.1093/eurheartj/ehz455. 4. Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2019; 40(39):3215-3217. doi: 10.1093/eurheartj/ehz687. 5. Orringer CE, Jacobson TA, Maki KC. National Lipid Association scientific statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high- or very-high ASCVD risk. J Clin Lipidol. 2019. doi: 10.1016/j.jacl.2019.10.014. 6. Institute for Clinical and Economic Review. Final Evidence Report. Additive Therapies for Cardiovascular Disease: Effectiveness and Value. https://icer-review.org/material/cvd-final-evidence-report/. Posted October 17, 2019. Accessed October 17, 2019. 7. Weintraub WS, Bhatt DL, Zhang A, et al. Cost-Effectiveness of icosapent ethyl in REDUCE-IT. Presented at American Heart Association Scientific Sessions 2019. November 16, 2019. Philadelphia, PA.	None	On December 13, 2019, Amarin announced a major milestone in preventative cardiology with a new FDA Approved indication for Vascepa® (icosapent ethyl). After more than a decade of development and testing, Vascepa in now the first and only drug approved by the FDA • as an adjunct to maximally tolerated statin therapy to reduce the risk of MI, stroke, coronary revascularization, and unstable angina requiring hospitalization in adult patients with elevated triglycerides =150 mg/dl and o Established cardiovascular disease, or o Diabetes and two or more additional risk factors for cardiovascular disease The FDA approval was based on the landmark REDUCE-IT® cardiovascular (CV) outcomes study, which showed, incremental to statin therapy, that Vascepa 4 g/day versus placebo provided a relative risk reduction of approximately 25% or more for the study’s primary and key secondary composite endpoints of major adverse cardiovascular events. Vascepa also showed robust relative risk reductions in each of the components of the primary composite endpoint, including myocardial infarction, stroke and cardiovascular death.1 The REDUCE-IT results have been characterized by leading physicians as the most significant advance in preventative cardiovascular care since the introduction of statin therapy. Based on the results of the Vascepa outcomes study, multiple professional societies have updated guidelines or issue advisories to incorporate Icosapent Ethyl, including the American Diabetes Association2, the European Society of Cardiology3,4, and the National Lipid Association.5 1. Bhatt DL, Steg PG, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med 2019;380:11-22. 2. American Diabetes Association. [web annotation]. Diabetes Care 2019;42(Suppl.1):S103–S123. https://hyp.is/JHhz_lCrEembFJ9LIVBZIw/care.diabetesjournals.org/content/42/Supplement_1/S103. Updated March 27, 2019. Accessed March 28, 2019. 3. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2019; ehz455. doi: 10.1093/eurheartj/ehz455. 4. Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2019; 40(39):3215-3217. doi: 10.1093/eurheartj/ehz687. 5. Orringer CE, Jacobson TA, Maki KC. National Lipid Association scientific statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high- or very-high ASCVD risk. J Clin Lipidol. 2019. doi: 10.1016/j.jacl.2019.10.014. 6. Institute for Clinical and Economic Review. Final Evidence Report. Additive Therapies for Cardiovascular Disease: Effectiveness and Value. https://icer-review.org/material/cvd-final-evidence-report/. Posted October 17, 2019. Accessed October 17, 2019. 7. Weintraub WS, Bhatt DL, Zhang A, et al. Cost-Effectiveness of icosapent ethyl in REDUCE-IT. Presented at American Heart Association Scientific Sessions 2019. November 16, 2019. Philadelphia, PA.	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000231	American Health Packaging	06/30/2021	60687012125	ACAMPROSATE CAL 333 MG DR TAB 30 UD	06/01/2021	8.84	67.81	None	Non-innovator Multiple Source Drug	14332	None	Market Conditions	None	No Change Improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	12/31/2021	60687034501	CALCITRIOL CAPSULE 0.25MCG 100UD	12/10/2021	9.90	73.78	None	Non-innovator Multiple Source Drug	5083	None	Market Conditions	None	No Change Improvement in the drug product	None	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=564	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	06/30/2021	60687054401	CLONAZEPAM 0.5 MG TAB 100 (10X10) UD	06/01/2021	35.32	59.00	None	Non-innovator Multiple Source Drug	18945	None	Market Conditions	None	No Change Improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	06/30/2021	60687055501	CLONAZEPAM 1 MG TAB 100 (10X10) UD	06/01/2021	35.32	59.00	None	Non-innovator Multiple Source Drug	13481	None	Market Conditions	None	No Change Improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	12/31/2021	68084092125	CYCLOSPORINE CAPSULE 100MG 30UD	11/26/2021	32.09	377.09	None	Non-innovator Multiple Source Drug	420	None	Market Conditions	None	No Change Improvement in the drug product	None	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=568	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	12/31/2021	68084087925	CYCLOSPORINE CAPSULE 25MG 30UD	11/26/2021	9.83	126.83	None	Non-innovator Multiple Source Drug	594	None	Market Conditions	None	No Change Improvement in the drug product	None	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=567	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	12/31/2021	68001026632	FLUOROURACIL INJECTION 5G/100ML(50MG/ML)	12/08/2021	0.03	51.40	None	Non-innovator Multiple Source Drug	12585	None	Market Conditions	None	No Change Improvement in the drug product	None	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=565	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	03/31/2021	60687060201	GABAPENTIN CAPS 400MG 100UD	02/05/2021	2.91	19.38	None	Non-innovator Multiple Source Drug	9276	None	Market Conditions	None	No Change Improvement in the drug product	None	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=541	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000231	American Health Packaging	12/31/2021	68084020201	PRIMIDONE TABLET 50MG 100UD	11/26/2021	26.87	81.25	None	Non-innovator Multiple Source Drug	2832	None	Market Conditions	None	No Change Improvement in the drug product	None	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=566	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
Rx0000128	American Regent	09/30/2021	00517250210	Caffeine & Sodium Benzoate, 250mg/ml 2mL SDV, 10pk	09/30/2021	20.60	230.90	None	Non-innovator Multiple Source Drug	7315	None	American Regent’s US Standards of Business Conduct (available at https://americanregent.com/media/3037/dsi_sobc-final_102020.pdf) reflects that it is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition.	None	NA	None	None	None	None	None	None	None	None	None	None	None	None
Rx0000128	American Regent	03/31/2021	00517065001	Injectafer Intravenous Solution 750 MG/15ML	01/01/2021	34.19	1173.86	02/15/2028	Single Source Drug	675579	None	American Regent’s US Standards of Business Conduct (available at https://www.americanregent.com/media/2747/us-sobc-112019.pdf) reflects that it is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition.	None	Not Applicabel	None	None	None	None	None	None	None	None	None	None	None	Injectafer is not an acquired product. American Regent is the NDA holder of this NDC.
Rx0000128	American Regent	12/31/2021	00517065001	Injectafer Intravenous Solution 750 MG/15ML	10/01/2021	35.22	1209.08	02/15/2028	Single Source Drug	760580	None	American Regent’s US Standards of Business Conduct (available at https://americanregent.com/media/3037/dsi_sobc-final_102020.pdf) reflects that it is committed to pricing its products fairly and appropriately, and acts independently when setting prices, by factoring in costs, market conditions, customer responses, and the state of competition.	None	NA	None	None	None	None	None	None	None	None	None	None	None	Injectafer is not an acquired product. American Regent is the NDA holder of this NDC.
Rx0000069	Amgen	03/31/2021	58406004401	Enbrel Mini, 50mg/mL, Cartridge (ML), 1 pack	01/22/2021	102.80	1492.04	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employs flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2021	58406045601	Enbrel Mini, 50mg/mL, Cartridge (ML), 1 pk	01/22/2021	102.80	1492.04	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employs flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2021	58406004404	Enbrel Mini, 50mg/mL, Cartridge (ML), 4 pack	01/22/2021	411.22	5968.16	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employs flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2021	58406045604	Enbrel Mini, 50mg/mL, Cartridge (ML), 4 pk	01/22/2021	411.22	5968.16	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employs flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2021	58406003201	Enbrel Sureclick, 50mg/mL, Pen Injector (ML), 1 pack	01/22/2021	102.80	1492.04	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employs flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2021	58406044501	Enbrel Sureclick, 50mg/mL, Pen Injector (ML), 1 pk	01/22/2021	102.80	1492.04	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employs flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2021	58406003204	Enbrel Sureclick, 50mg/mL, Pen Injector (ML), 4 pack	01/22/2021	411.22	5968.16	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employs flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2021	58406044504	Enbrel Sureclick, 50mg/mL, Pen Injector (ML), 4 pk	01/22/2021	411.22	5968.16	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employs flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2021	58406042534	Enbrel, 25mg (1 mL), Vial (EA), 4 pk	01/22/2021	205.61	2984.08	04/24/2029	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employs flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2021	58406042541	Enbrel, 25mg (1mL), Vial (EA), 1 pk	01/22/2021	51.40	746.02	04/24/2029	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employs flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2021	58406001001	Enbrel, 25mg/0.5mL, Syringe (ML), 1 pack	01/22/2021	51.40	746.02	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employs flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2021	58406001004	Enbrel, 25mg/0.5mL, Syringe (ML), 4 pack	01/22/2021	205.61	2984.08	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employs flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available.The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2021	58406005501	Enbrel, 25mg/0.5mL, Vial (EA), 1 pack	01/22/2021	51.40	746.02	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employs flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2021	58406005504	Enbrel, 25mg/0.5mL, Vial (EA), 4 pack	01/22/2021	205.61	2984.08	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employs flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2021	58406045501	Enbrel, 25mg/mL, Syringe (ML), 1 pk	01/22/2021	51.40	746.02	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employs flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2021	58406045504	Enbrel, 25mg/mL, Syringe (ML), 4 pk	01/22/2021	205.61	2984.08	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employs flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2021	58406002101	Enbrel, 50mg/mL, Syringe (ML), 1 pack	01/22/2021	102.80	1492.04	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employs flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2021	58406043501	Enbrel, 50mg/mL, Syringe (ML), 1 pk	01/22/2021	102.80	1492.04	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employs flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2021	58406002104	Enbrel, 50mg/mL, Syringe (ML), 4 pack	01/22/2021	411.22	5968.16	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employs flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2021	58406043504	Enbrel, 50mg/mL, Syringe (ML), 4 pk	01/22/2021	411.22	5968.16	10/19/2037	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employs flexible pricing approaches to ensure patient access	None	None	1	None	None	None	None	None	None	None	None	None	None	Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Enbrel reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	09/30/2021	59572063255	Otezla, 10mg (4)-20mg (4)-30g (47), Tablet Dose Pack, 55 pack	08/18/2021	92.58	3950.06	05/29/2034	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employs flexible pricing approaches to ensure patient access	None	None	1	11/21/2019	Celgene	13400000000	None	None	3398.00	3283.09	2015	1875.00	None	This is the old Celgene NDC that will be discontinued after product runs out in channel. Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Otezla reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	09/30/2021	59572063106	Otezla, 30mg, Tablet, 60 pack	08/18/2021	92.58	3950.06	05/29/2034	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employs flexible pricing approaches to ensure patient access	None	None	1	11/21/2019	Celgene	13400000000	None	None	3398.00	3283.09	2014	1875.00	None	This is the old Celgene NDC that will be discontinued after product runs out in channel. Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Otezla reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2021	55513036955	Otezla, 10mg (4)-20mg (4)-30g (47), Tablet Dose Pack, 55 pack	01/22/2021	265.79	3857.48	05/29/2034	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employs flexible pricing approaches to ensure patient access	None	None	1	11/21/2019	Celgene	13400000000	None	None	3398.00	3283.09	2020	3591.69	None	This is a new Amgen NDC that we are reassigning from the old Celgene NDC. Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Otezla reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	09/30/2021	55513036955	Otezla, 10mg (4)-20mg (4)-30g (47), Tablet Dose Pack, 55 pack	08/18/2021	92.58	3950.06	05/29/2034	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employs flexible pricing approaches to ensure patient access	None	None	1	11/21/2019	Celgene	13400000000	None	None	3398.00	3283.09	2020	3591.69	None	This is a new Amgen NDC that we are reassigning from the old Celgene NDC. Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Otezla reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2021	59572063255	Otezla, 10mg (4)-20mg (4)-30g (47), Tablet Dose Pack, 55 pk	01/22/2021	265.79	3857.48	05/29/2034	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employs flexible pricing approaches to ensure patient access	None	None	1	11/21/2019	Celgene	13400000000	None	None	3398.00	3283.09	2015	1875.00	None	This is the old Celgene NDC that will be discontinued after product runs out in channel. Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Otezla reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2021	55513013760	Otezla, 30mg, Tablet, 60 pack	01/22/2021	265.79	3857.48	05/29/2034	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employs flexible pricing approaches to ensure patient access	None	None	1	11/21/2019	Celgene	13400000000	None	None	3398.00	3283.09	2020	3591.69	None	This is a new Amgen NDC that we are reassigning from the old Celgene NDC. Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Otezla reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	09/30/2021	55513013760	Otezla, 30mg, Tablet, 60 pack	08/18/2021	92.58	3950.06	05/29/2034	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employs flexible pricing approaches to ensure patient access	None	None	1	11/21/2019	Celgene	13400000000	None	None	3398.00	3283.09	2020	3591.69	None	This is a new Amgen NDC that we are reassigning from the old Celgene NDC. Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Otezla reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000069	Amgen	03/31/2021	59572063106	Otezla, 30mg, Tablet, 60 pk	01/22/2021	265.79	3857.48	05/29/2034	Single Source Drug	None	1	Amgen understands that the cost of prescription drugs is a concern for many people, and we are committed to the responsible pricing of our medicines. Our approach to pricing across the globe is underpinned by two simple core principles: I. Pricing our products according to the value they deliver II. Employs flexible pricing approaches to ensure patient access	None	None	1	11/21/2019	Celgene	13400000000	None	None	3398.00	3283.09	2014	1875.00	None	This is the old Celgene NDC that will be discontinued after product runs out in channel. Unit Sales Volume and Change Improvement: Per CA Health & Safety Code §127681(c) Amgen respectfully declines to submit this information, as it is not otherwise in the public domain or publicly available. The patent expiration information provided for Otezla reflects the date for the latest-expiring material patents publicly disclosed in Amgen financial disclosures, including method of treatment and manufacture patents.
Rx0000122	Amneal Pharmaceuticals	03/31/2021	64896066930	Emverm Oral Tablet Chewable 100 MG, Package size of 1	02/15/2021	46.07	511.38	None	Single Source Drug	None	1	None	1	None	1	05/07/2018	IMPAX	None	1	This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company.	405.53	369.00	2017	369.00	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2021	64896069701	oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 10 MG, Package size of 100	02/15/2021	96.80	583.21	None	Single Source Drug	None	1	None	1	None	1	05/07/2018	IMPAX	None	1	This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company.	381.56	381.56	2013	278.45	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2021	64896069713	oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 10 MG, Package size of 60	02/15/2021	58.08	349.93	None	Single Source Drug	None	1	None	1	None	1	05/07/2018	IMPAX	None	1	This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company.	228.94	228.94	2013	167.07	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2021	64896069801	oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 15 MG, Package size of 100	02/15/2021	134.23	808.75	None	Single Source Drug	None	1	None	1	None	1	05/07/2018	IMPAX	None	1	This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company.	529.13	529.13	2013	386.15	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2021	64896069813	oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 15 MG, Package size of 60	02/15/2021	80.54	485.26	None	Single Source Drug	None	1	None	1	None	1	05/07/2018	IMPAX	None	1	This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company.	317.48	317.48	2013	231.69	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2021	64896069901	oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 20 MG, Package size of 100	02/15/2021	171.68	1034.38	None	Single Source Drug	None	1	None	1	None	1	05/07/2018	IMPAX	None	1	This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company.	676.74	676.74	2013	493.86	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2021	64896069913	oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 20 MG, Package size of 60	02/15/2021	103.01	620.63	None	Single Source Drug	None	1	None	1	None	1	05/07/2018	IMPAX	None	1	This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company.	406.05	406.05	2013	296.32	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2021	64896070001	oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 30 MG, Package size of 100	02/15/2021	247.10	1488.82	None	Single Source Drug	None	1	None	1	None	1	05/07/2018	IMPAX	None	1	This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company.	974.06	974.06	2013	710.84	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2021	64896070013	oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 30 MG, Package size of 60	02/15/2021	148.26	893.30	None	Single Source Drug	None	1	None	1	None	1	05/07/2018	IMPAX	None	1	This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company.	584.44	584.44	2013	426.50	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2021	64896070101	oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 40 MG, Package size of 100	02/15/2021	322.53	1943.28	None	Single Source Drug	None	1	None	1	None	1	05/07/2018	IMPAX	None	1	This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company.	1271.39	1271.39	2013	927.82	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2021	64896070113	oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 40 MG, Package size of 60	02/15/2021	193.52	1165.97	None	Single Source Drug	None	1	None	1	None	1	05/07/2018	IMPAX	None	1	This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company.	762.84	762.84	2013	556.69	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2021	64896069501	oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 5 MG, Package size of 100	02/15/2021	50.41	303.72	None	Single Source Drug	None	1	None	1	None	1	05/07/2018	IMPAX	None	1	This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company.	198.71	198.71	2013	145.00	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2021	64896069513	oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 5 MG, Package size of 60	02/15/2021	30.24	182.22	None	Single Source Drug	None	1	None	1	None	1	05/07/2018	IMPAX	None	1	This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company.	119.22	119.22	2013	87.01	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2021	64896069601	oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 7.5 MG, Package size of 100	02/15/2021	73.60	443.44	None	Single Source Drug	None	1	None	1	None	1	05/07/2018	IMPAX	None	1	This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company.	290.12	290.12	2013	211.72	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2021	64896069613	oxyMORphone HCl ER Oral Tablet Extended Release 12 Hour 7.5 MG, Package size of 60	02/15/2021	44.16	266.06	None	Single Source Drug	None	1	None	1	None	1	05/07/2018	IMPAX	None	1	This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company.	174.07	174.07	2013	127.03	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2021	64896066101	Rytary Oral Capsule Extended Release 23.75-95 MG, Package size of 100	02/15/2021	15.07	350.05	12/26/2028	Single Source Drug	None	1	None	1	None	1	05/07/2018	IMPAX	None	1	This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company.	291.68	258.41	2015	230.00	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2021	64896066201	Rytary Oral Capsule Extended Release 36.25-145 MG, Package size of 100	02/15/2021	15.07	350.05	12/26/2028	Single Source Drug	None	1	None	1	None	1	05/07/2018	IMPAX	None	1	This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company.	291.68	258.41	2015	230.00	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2021	64896066301	Rytary Oral Capsule Extended Release 48.75-195 MG, Package size of 100	02/15/2021	15.07	350.05	12/26/2028	Single Source Drug	None	1	None	1	None	1	05/07/2018	IMPAX	None	1	This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company.	291.68	258.41	2015	230.00	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2021	64896066401	Rytary Oral Capsule Extended Release 61.25-245 MG, Package size of 100	02/15/2021	18.94	439.86	12/26/2028	Single Source Drug	None	1	None	1	None	1	05/07/2018	IMPAX	None	1	This deal was a merger in which Impax shareholders received 25% of the outstanding shares of the new company.	366.51	324.69	2015	289.00	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2021	60846080501	Unithroid Oral Tablet 100 MCG, Package size of 100	02/15/2021	30.42	337.72	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2021	60846080601	Unithroid Oral Tablet 112 MCG, Package size of 100	02/15/2021	30.48	338.40	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2021	60846080701	Unithroid Oral Tablet 125 MCG, Package size of 100	02/15/2021	30.53	338.96	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2021	60846080801	Unithroid Oral Tablet 137 MCG, Package size of 100	02/15/2021	30.57	339.32	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2021	60846080901	Unithroid Oral Tablet 150 MCG, Package size of 100	02/15/2021	30.59	339.59	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2021	60846081001	Unithroid Oral Tablet 175 MCG, Package size of 100	02/15/2021	30.64	340.10	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2021	60846081101	Unithroid Oral Tablet 200 MCG, Package size of 100	02/15/2021	30.67	340.42	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2021	60846080101	Unithroid Oral Tablet 25 MCG, Package size of 100	02/15/2021	30.25	335.81	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2021	60846081201	Unithroid Oral Tablet 300 MCG, Package size of 100	02/15/2021	30.70	340.76	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2021	60846080201	Unithroid Oral Tablet 50 MCG, Package size of 100	02/15/2021	30.27	336.03	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2021	60846080301	Unithroid Oral Tablet 75 MCG, Package size of 100	02/15/2021	30.30	336.41	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000122	Amneal Pharmaceuticals	03/31/2021	60846080401	Unithroid Oral Tablet 88 MCG, Package size of 100	02/15/2021	30.37	337.15	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000176	ANIP	03/31/2021	62559067030	Arimidex (anastrozole) Tablets 1.0mg-30	03/05/2021	134.78	1632.37	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000176	ANIP	03/31/2021	62559052201	Inderal LA (propranolol hydrochloride) Long-Acting Cap 120mg-100	03/05/2021	670.45	8119.84	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000176	ANIP	03/31/2021	62559052301	Inderal LA (propranolol hydrochloride) Long-Acting Cap 160mg-100	03/05/2021	699.89	8476.47	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000176	ANIP	03/31/2021	62559052101	Inderal LA (propranolol hydrochloride) Long-Acting Capsules 80mg-100	03/05/2021	608.80	7373.21	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000176	ANIP	03/31/2021	62559052001	Inderal LA (propranolol Hydrocholoride) Long-Acting Capsules 60mg-100	03/05/2021	521.22	6312.57	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000176	ANIP	03/31/2021	62559060130	Inderal XL (propranolol hydrochloride) Extended Release Capsule 120mg-30	03/05/2021	180.34	2184.08	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000176	ANIP	03/31/2021	62559060030	Inderal XL (propranolol hydrochloride) Extended Release Capsule 80mg-30	03/05/2021	180.34	2184.08	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000176	ANIP	03/31/2021	62559059130	Innopran XL (propranolol hydrochloride) Extended Release Capsules 120mg-30	03/05/2021	180.34	2184.08	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000176	ANIP	03/31/2021	62559059030	Innopran XL (propranolol hydrochloride) Extended Release Capsules 80mg-30	03/05/2021	180.34	2184.08	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000271	Apotex Corp	12/31/2021	60505437703	PAXIL CR FCT 12.5MG 30BTL USA	10/19/2021	21.55	239.42	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000271	Apotex Corp	12/31/2021	60505437803	PAXIL CR FCT 25MG 30BTL USA	10/19/2021	22.48	249.82	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000271	Apotex Corp	12/31/2021	60505437903	PAXIL CR FCT 37.5MG 30BTL USA	10/19/2021	23.16	257.35	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000271	Apotex Corp	12/31/2021	60505451703	PAXIL FCT 10MG 30BTL USA	10/19/2021	20.92	232.45	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000271	Apotex Corp	12/31/2021	60505451803	PAXIL FCT 20MG 30BTL USA	10/19/2021	21.83	242.52	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000271	Apotex Corp	12/31/2021	60505451903	PAXIL FCT 30MG 30BTL USA	10/19/2021	22.49	249.87	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000271	Apotex Corp	12/31/2021	60505452003	PAXIL FCT 40MG 30BTL USA	10/19/2021	23.76	263.95	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000271	Apotex Corp	12/31/2021	60505040205	PAXIL O/SUSP 10MG/5ML 250ML BTL USA1	10/19/2021	36.32	403.52	None	Innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000271	Apotex Corp	06/30/2021	60505003307	PENTOXIFYLLINE XR Film Coated Table (FCT) 400MG 500 BTL	04/20/2021	71.82	205.20	None	Non-innovator Multiple Source Drug	38316	None	None	1	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000132	Arbor Pharmaceuticals, LLC	03/31/2021	24338001018	Bidil 20mg/37.5mg Tablet 180 Count Bottle	01/01/2021	20.10	690.06	None	Innovator Multiple Source Drug	51766	None	PBM Rebates; Increased Costs; Government Program Fees; Previous Price Increases	None	None	None	None	None	None	None	None	None	None	None	None	None	We are submitting under protest as we do not believe that we are required to report. There was no effective price in 2019 as the price on 1/1/2019 was the only price available.
Rx0000075	Assertio Therapeutics, Inc.	03/31/2021	13913001201	Cambia (diclofenac potassium) 50MG Oral 1 Packet	01/03/2021	8.23	91.34	06/16/2026	Single Source Drug	None	1	Our pricing is guided by the value our products bring to patients and an understanding of the environment in which we operate. The following financial and nonfinancial factors, along with a narrative description and explanation of these factors, influenced our decisions to take a price action: (1) Covering Operating Expenses. In order to maintain a commercial enterprise, our revenue, at a minimum, must cover operating expenses. We consider covering operating expenses in our decision around the pricing of our products. (2) Recouping Development Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs, recoup the costs expended to develop our products. We consider covering development costs and expenses in our decision around the pricing of our products. (3) Covering and Funding Acquisition Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs and developmental costs, cover the costs expended to acquire drug products. We consider covering acquisition costs in our decision around the pricing of our products. (4) Supporting Investment in New Products. In order to maintain a commercial enterprise, we must invest money to develop and bring new products to market to help patients. We consider the costs to bring new products to market to meet unmet medical needs in our decisions around pricing our products. (5) Supporting Investment in Existing Products. In order to maintain a commercial enterprise, we must invest money to improve our existing products to bring improved products to market to help patients. We consider the costs to improve our existing products in our decisions around the pricing of our products. (6) Discounts and Rebates: We pay rebates and discounts to various stakeholders in the supply chain in connection with the sale of our products, including pharmacy benefits managers, health insurers and health plans, including government payors like California's Medicaid program, as well as wholesalers and pharmacies. Collectively, these price concessions represent substantial dollars, and we consider them in our decisions around pricing our products. (7) Inflation: We consider the rate of annual inflation in our decisions around pricing our products.	None	None - see cost increase factors statement.	None	None	None	None	None	None	None	None	None	None	None	This drug was not acquired in the past five years. Comment on data element #8: While this is an active NDC in the compendia, we did not have any sales of the single unit NDC. We attempted to put 0 in this field but the validation failed so based on guidance from CA we are indicating non-public in data element #9. There were no US Sales of this NDC in 2020.
Rx0000075	Assertio Therapeutics, Inc.	03/31/2021	13913001203	Cambia (diclofenac potassium) 50MG Oral 9 Packets	01/03/2021	74.05	822.03	06/16/2026	Single Source Drug	87045	None	Our pricing is guided by the value our products bring to patients and an understanding of the environment in which we operate. The following financial and nonfinancial factors, along with a narrative description and explanation of these factors, influenced our decisions to take a price action: (1) Covering Operating Expenses. In order to maintain a commercial enterprise, our revenue, at a minimum, must cover operating expenses. We consider covering operating expenses in our decision around the pricing of our products. (2) Recouping Development Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs, recoup the costs expended to develop our products. We consider covering development costs and expenses in our decision around the pricing of our products. (3) Covering and Funding Acquisition Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs and developmental costs, cover the costs expended to acquire drug products. We consider covering acquisition costs in our decision around the pricing of our products. (4) Supporting Investment in New Products. In order to maintain a commercial enterprise, we must invest money to develop and bring new products to market to help patients. We consider the costs to bring new products to market to meet unmet medical needs in our decisions around pricing our products. (5) Supporting Investment in Existing Products. In order to maintain a commercial enterprise, we must invest money to improve our existing products to bring improved products to market to help patients. We consider the costs to improve our existing products in our decisions around the pricing of our products. (6) Discounts and Rebates: We pay rebates and discounts to various stakeholders in the supply chain in connection with the sale of our products, including pharmacy benefits managers, health insurers and health plans, including government payors like California's Medicaid program, as well as wholesalers and pharmacies. Collectively, these price concessions represent substantial dollars, and we consider them in our decisions around pricing our products. (7) Inflation: We consider the rate of annual inflation in our decisions around pricing our products.	None	None - see cost increase factors statement.	None	None	None	None	None	None	None	None	None	None	None	This drug was not acquired in the past five years
Rx0000075	Assertio Therapeutics, Inc.	03/31/2021	13913000812	Zipsor (diclofenac potassium) 25MG Oral Capsule 120 Ct Bottle	01/03/2021	155.48	1726.03	02/24/2029	Single Source Drug	19458	None	Our pricing is guided by the value our products bring to patients and an understanding of the environment in which we operate. The following financial and nonfinancial factors, along with a narrative description and explanation of these factors, influenced our decisions to take a price action: (1) Covering Operating Expenses. In order to maintain a commercial enterprise, our revenue, at a minimum, must cover operating expenses. We consider covering operating expenses in our decision around the pricing of our products. (2) Recouping Development Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs, recoup the costs expended to develop our products. We consider covering development costs and expenses in our decision around the pricing of our products. (3) Covering and Funding Acquisition Costs. In order to maintain a commercial enterprise, our revenue, must, in addition to covering operating costs and developmental costs, cover the costs expended to acquire drug products. We consider covering acquisition costs in our decision around the pricing of our products. (4) Supporting Investment in New Products. In order to maintain a commercial enterprise, we must invest money to develop and bring new products to market to help patients. We consider the costs to bring new products to market to meet unmet medical needs in our decisions around pricing our products. (5) Supporting Investment in Existing Products. In order to maintain a commercial enterprise, we must invest money to improve our existing products to bring improved products to market to help patients. We consider the costs to improve our existing products in our decisions around the pricing of our products. (6) Discounts and Rebates: We pay rebates and discounts to various stakeholders in the supply chain in connection with the sale of our products, including pharmacy benefits managers, health insurers and health plans, including government payors like California's Medicaid program, as well as wholesalers and pharmacies. Collectively, these price concessions represent substantial dollars, and we consider them in our decisions around pricing our products. (7) Inflation: We consider the rate of annual inflation in our decisions around pricing our products.	None	None - see cost increase factors statement.	None	None	None	None	None	None	None	None	None	None	None	This drug was not acquired in the past five years
Rx0000048	Astellas Pharma US, Inc.	03/31/2021	00469260130	Myrbetriq® 25mg 30 Tablet	01/05/2021	12.15	417.19	03/28/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Astellas believes is otherwise in the public domain or publicly available. As such, columns 8, 10 and 12 are intentionally left blank. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of March 31, 2021. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. The date of 3/28/2030, as reflected in FDA’s Orange Book, represents the patent expiry date of 9/28/2029 and an additional 6 months of pediatric exclusivity granted by the FDA on 3/15/2021. (3) This product was not acquired, therefore columns 14-22 are intentionally left blank.
Rx0000048	Astellas Pharma US, Inc.	03/31/2021	00469260190	Myrbetriq® 25mg 90 Tablet	01/05/2021	36.45	1251.57	03/28/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Astellas believes is otherwise in the public domain or publicly available. As such, columns 8, 10 and 12 are intentionally left blank. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of March 31, 2021. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. The date of 3/28/2030, as reflected in FDA’s Orange Book, represents the patent expiry date of 9/28/2029 and an additional 6 months of pediatric exclusivity granted by the FDA on 3/15/2021. (3) This product was not acquired, therefore columns 14-22 are intentionally left blank.
Rx0000048	Astellas Pharma US, Inc.	03/31/2021	00469260230	Myrbetriq® 50mg 30 Tablet	01/05/2021	12.15	417.19	03/28/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Astellas believes is otherwise in the public domain or publicly available. As such, columns 8, 10 and 12 are intentionally left blank. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of March 31, 2021. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. The date of 3/28/2030, as reflected in FDA’s Orange Book, represents the patent expiry date of 9/28/2029 and an additional 6 months of pediatric exclusivity granted by the FDA on 3/15/2021. (3) This product was not acquired, therefore columns 14-22 are intentionally left blank.
Rx0000048	Astellas Pharma US, Inc.	03/31/2021	00469260290	Myrbetriq® 50mg 90 Tablet	01/05/2021	36.45	1251.57	03/28/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Astellas believes is otherwise in the public domain or publicly available. As such, columns 8, 10 and 12 are intentionally left blank. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of March 31, 2021. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. The date of 3/28/2030, as reflected in FDA’s Orange Book, represents the patent expiry date of 9/28/2029 and an additional 6 months of pediatric exclusivity granted by the FDA on 3/15/2021. (3) This product was not acquired, therefore columns 14-22 are intentionally left blank.
Rx0000058	Avanir Pharmaceuiticals	03/31/2021	64597030160	Nuedexta Oral Capsule 20-10 mg 60 pack	01/01/2021	84.60	1335.00	08/13/2026	Single Source Drug	None	1	Avanir is committed to making responsible pricing determinations, and in so doing we consider a range of factors.  As a general matter, our WAC determinations are influenced by research and development costs (including investments in product and portfolio innovation); manufacturing, distribution, and regulatory costs; market and competitive factors; downstream demands for price concessions/rebates; value to patients and the health care system; and access and affordability.  Pricing decisions at Avanir are made at the executive level in adherence with all federal and state laws.	None	This WAC increase is not necessitated by a change or improvement in the prescription drug.	None	None	None	None	None	None	None	None	None	None	None	The reason for the blank acquisition-related fields is that Neudexta was not acquired.
Rx0000277	Avion Pharmaceuticals, LLC	03/31/2021	75854060228	BALCOLTRA Oral Tablet 0.1-20 MG-MCG	01/31/2021	18.57	224.97	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Columns 14 thru 22 were not completed as the product was not acquired within the last 5 years.
Rx0000277	Avion Pharmaceuticals, LLC	03/31/2021	75854060203	BALCOLTRA Oral Tablet 0.1-20 MG-MCG (21)	01/31/2021	55.73	674.92	None	Non-innovator Multiple Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Columns 14 thru 22 were not completed as the product was not acquired within the last 5 years.